Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.

Autor: Thill M; Agaplesion Markus Krankenhaus, Frankfurt, Germany., Zahn MO; MVZ Onkologische Kooperation Harz, Goslar, Germany., Welt A; Universitätsklinikum Essen, Essen, Germany., Stickeler E; Universitätsklinikum Aachen, Aachen, Germany., Nusch A; Praxis für Hämatologie und internistische Onkologie, Ratingen, Germany., Fietz T; Schwerpunktpraxis für Hämatologie und internistische Onkologie, Singen, Germany., Rauh J; Gemeinschaftspraxis Innere Medizin, Witten, Germany., Wetzel N; iOMEDICO, Freiburg, Germany., Kruggel L; iOMEDICO, Freiburg, Germany., Jänicke M; iOMEDICO, Freiburg, Germany., Marschner N; Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany., Harbeck N; Brustzentrum, Frauenklinik LMU Klinikum, Munich, Germany., Wöckel A; Universitätsklinikum Würzburg, Würzburg, Germany., Decker T; Onkologie Ravensburg, Praxis für Hämatologie und Onkologie GbR, Ravensburg, Germany. thomas.decker@onkonet.eu.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Apr; Vol. 198 (3), pp. 545-553. Date of Electronic Publication: 2023 Feb 18.
DOI: 10.1007/s10549-023-06882-7
Abstrakt: Purpose: Evidence about routine treatment and outcome of patients with invasive lobular cancer (ILC) is limited, especially regarding metastatic disease. Here we present prospective real-world data of patients with metastatic ILC (mILC) as compared to patients with metastatic invasive ductal cancer (mIDC) receiving systemic therapy in routine care in Germany.
Methods: Prospective data on patient and tumor characteristics, treatments, and outcomes of patients with mILC (n = 466) and mIDC (n = 2100), recruited between 2007 and 2021 into the Tumor Registry Breast Cancer/OPAL were analyzed.
Results: Compared to mIDCs, patients with mILC were older at start of first-line treatment (median 69 vs. 63 years) and had more often lower grade (G1/G2: 72.8% vs. 51.2%), hormone receptor (HR)-positive (83.7% vs. 73.2%) and less often HER2-positive (14.2% vs. 28.6%) tumors, which metastasized more frequently to the bone (19.7% vs. 14.5%) or peritoneum (9.9% vs. 2.0%), and less frequently to the lungs (0.9% vs. 4.0%). Median OS of patients with mILC (n = 209) and mIDC (n = 1158) was 30.2 months [95% confidence interval (CI) 25.3, 36.0] and 33.7 months [95% CI 30.3, 37.9], respectively. Multivariate survival analysis did not show a significant prognostic impact of the histological subtype [HR mILC vs. mIDC 1.18 (95% CI 0.97-1.42)].
Conclusion: Overall, our real-world data confirm clinicopathological differences between mILC and mIDC breast cancer patients. Despite patients with mILC presenting with some favorable prognostic factors, ILC histopathology was not associated with a better clinical outcome in multivariate analysis, suggesting the need for more tailored treatment strategies for patients with the lobular subtype.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: